[go: up one dir, main page]

NO20084452L - Intranasal influensavaksine basert pa virosomer - Google Patents

Intranasal influensavaksine basert pa virosomer

Info

Publication number
NO20084452L
NO20084452L NO20084452A NO20084452A NO20084452L NO 20084452 L NO20084452 L NO 20084452L NO 20084452 A NO20084452 A NO 20084452A NO 20084452 A NO20084452 A NO 20084452A NO 20084452 L NO20084452 L NO 20084452L
Authority
NO
Norway
Prior art keywords
composition
virosomes
influenza
reconstituted
inhalation administration
Prior art date
Application number
NO20084452A
Other languages
English (en)
Norwegian (no)
Inventor
Alexander J Kersten
Lisya Gerez
Pieter J Schoen
Jozef J P Nauta
Dorine H Van Rheineck Leyssius
Original Assignee
Solvay Biolog Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Biolog Bv filed Critical Solvay Biolog Bv
Publication of NO20084452L publication Critical patent/NO20084452L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO20084452A 2006-03-22 2008-10-22 Intranasal influensavaksine basert pa virosomer NO20084452L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78446206P 2006-03-22 2006-03-22
EP06111534 2006-03-22
PCT/EP2007/052690 WO2007107585A1 (en) 2006-03-22 2007-03-21 Intranasal influenza vaccine based on virosomes

Publications (1)

Publication Number Publication Date
NO20084452L true NO20084452L (no) 2008-10-22

Family

ID=38038698

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084452A NO20084452L (no) 2006-03-22 2008-10-22 Intranasal influensavaksine basert pa virosomer

Country Status (21)

Country Link
EP (2) EP2158921B1 (de)
JP (1) JP5285595B2 (de)
KR (1) KR20090016659A (de)
AR (1) AR059972A1 (de)
AT (2) ATE539766T1 (de)
AU (1) AU2007228736B2 (de)
BR (1) BRPI0709864A2 (de)
CA (1) CA2646895A1 (de)
DE (1) DE602007003815D1 (de)
DK (2) DK2158921T3 (de)
EA (1) EA014532B1 (de)
ES (2) ES2375436T3 (de)
HR (2) HRP20100144T1 (de)
IL (1) IL193840A (de)
MY (1) MY142996A (de)
NO (1) NO20084452L (de)
PL (2) PL2158921T3 (de)
PT (2) PT2158921E (de)
SA (1) SA07280116B1 (de)
SI (2) SI2158921T1 (de)
WO (1) WO2007107585A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110150926A1 (en) * 2008-08-01 2011-06-23 Mohammed Alsharifi Influenza vaccines
JP2014511119A (ja) * 2010-11-02 2014-05-08 インムノライフ，エセ．ア．デ セー．ウーベ． Ｈ１ｎ１亜型インフルエンザパンデミックウイルスに対する新型ワクチン
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
EP1447080A1 (de) * 2003-02-13 2004-08-18 Bestewil Holding B.V. Methode zur Herstellung von Virosomen-artigen Partikeln
AR056245A1 (es) * 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante

Also Published As

Publication number Publication date
JP2009530351A (ja) 2009-08-27
HRP20100144T1 (hr) 2010-04-30
ES2375436T3 (es) 2012-02-29
EP1996229A1 (de) 2008-12-03
AU2007228736B2 (en) 2011-12-15
AU2007228736A1 (en) 2007-09-27
SI1996229T1 (sl) 2010-04-30
DK1996229T3 (da) 2010-05-03
PL1996229T3 (pl) 2010-05-31
DE602007003815D1 (en) 2010-01-28
EP1996229B1 (de) 2009-12-16
IL193840A0 (en) 2011-08-01
PT2158921E (pt) 2012-03-27
BRPI0709864A2 (pt) 2011-07-26
AR059972A1 (es) 2008-05-14
ES2338382T3 (es) 2010-05-06
MY142996A (en) 2011-02-14
EP2158921B1 (de) 2012-01-04
PT1996229E (pt) 2010-03-16
EA200870361A1 (ru) 2009-02-27
ATE539766T1 (de) 2012-01-15
SI2158921T1 (sl) 2012-03-30
EP2158921A1 (de) 2010-03-03
JP5285595B2 (ja) 2013-09-11
ATE451931T1 (de) 2010-01-15
HRP20120013T1 (hr) 2012-01-31
PL2158921T3 (pl) 2012-06-29
EA014532B1 (ru) 2010-12-30
IL193840A (en) 2011-10-31
KR20090016659A (ko) 2009-02-17
ES2375436T8 (es) 2012-03-15
WO2007107585A1 (en) 2007-09-27
CA2646895A1 (en) 2007-09-27
SA07280116B1 (ar) 2010-10-19
DK2158921T3 (da) 2012-05-07

Similar Documents

Publication Publication Date Title
Quiñones-Parra et al. Universal immunity to influenza must outwit immune evasion
Sambhara et al. Heterosubtypic Immunity against Human Influenza A Viruses, Including Recently Emerged Avian H5 and H9 Viruses, Induced by FLU–ISCOM Vaccine in Mice Requires both Cytotoxic T-Lymphocyte and Macrophage Function
Ghendon et al. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines
Rimmelzwaan et al. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development
Geeraedts et al. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs
Johansson et al. Changing perspective on immunization against influenza
DK1216053T3 (da) Influenzavaccine
Hillaire et al. Clearance of influenza virus infections by T cells: risk of collateral damage?
AU2011280259A8 (en) Influenza vaccine
EA023662B1 (ru) Вакцины против гриппа со сниженным количеством сквалена
Budimir et al. Heterosubtypic cross‐protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration
NO20084452L (no) Intranasal influensavaksine basert pa virosomer
Jones et al. A nasal Proteosome™ influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity
Bhatnagar et al. Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice
Wang et al. Bursin-like peptide (BLP) enhances H9N2 influenza vaccine induced humoral and cell mediated immune responses
WO2006062637A3 (en) Influenza vaccination
ATE508185T1 (de) Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus
US20180016560A1 (en) Novel influenza virus
UA93236C2 (ru) Композиция для одноразового интраназального введения, которая содержит виросомы гриппа, образованные из реконструированных оболочек указанного вируса, применение указанных виросом, вакцина, которая содержит указанную композицию, и средство для интраназального или ингаляционного введения
Gambaryan et al. Mutations in hemagglutinin and polymerase alter the virulence of pandemic A (H1N1) influenza virus
NZ580603A (en) Intradermal influenza vaccine
He et al. Adenovirus-based vaccines against avian-origin H5N1 influenza viruses
Nguyen et al. Towards future T cell-mediated influenza vaccines
Sun et al. Effect of receptor binding specificity on the immunogenicity and protective efficacy of influenza virus A H1 vaccines
Xu et al. Host Immunity against Influenza Virus Infection

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBOTT BIOLOGICALS BV, NL

FC2A Withdrawal, rejection or dismissal of laid open patent application